Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 4-Week radiation course be as good as 5 weeks for prostate cancer?

NCT ID NCT07483658

Disease control Sponsor: CHU de Quebec-Universite Laval Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study compares two radiotherapy schedules for men whose prostate cancer has returned after surgery. The standard treatment takes 5 weeks, while the shorter one takes 4 weeks. Researchers want to see if the shorter schedule causes no more side effects and controls the cancer just as well. About 434 men will take part, and the study will run for 12 years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiotherapy (external beam radiation)
What this could lead to
If successful, this could offer men with recurrent prostate cancer a shorter, more convenient radiotherapy schedule with similar safety and cancer control.
What could go wrong
This is a non-inferiority trial, so the shorter schedule may prove less effective or cause different side effects. Results will take years, and the study is not yet recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 434 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Feb 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed prostate adenocarcinoma. * Prior radical prostatectomy with detectable PSA (≥0.2 ng/mL). * No evidence of distant metastasis (confirmed via bone scan and CT/MRI or TEP-PSMA if PSA is above 0.5 ng /ml). * Patient with Nodal recurrence within the pelvis are eligible * ECOG performance status 0-2. * Age ≥ 18 years. * Adequate baseline renal, hepatic, and hematologic function. Exclusion Criteria: * Prior pelvic radiotherapy. * Macroscopic local relapse on imaging * Presence of metastatic disease. * Active inflammatory bowel disease or other GI conditions predisposing to radiation toxicity. * Uncontrolled comorbidities affecting study participation. * Prior systemic therapy for recurrent prostate cancer (except ADT within 6 months).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biochemical recurrence of malignant neoplasm of prostate are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

digestive system disorder metastatic malignant neoplasm metastatic neoplasm Neoplasm Recurrence, Local prostate adenocarcinoma prostate cancer prostate neoplasm radiation injury urinary system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biochemical recurrence of malignant neoplasm of prostate Neoplasm recurrence, local Prostate cancer Prostate cancer (post prostatectomy) Prostatic neoplasms Reccurent/metastatic solid tumor disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Québec-Université Laval

    RECRUITING

    Québec, Quebec, G1G 5X1, Canada

  • Gatineau Hospital

    NOT_YET_RECRUITING

    Gatineau, Quebec, Canada

  • Hôpital Général Juif

    NOT_YET_RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

  • McGill University Health Centre

    NOT_YET_RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.